Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.46 |
| ▸ | CCR2 | P41597 | 6/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518803 | 1.00 | ROCK2 (0.52) | ROCK2ROCK1CCR2SCN1ASCN8A | |
| SCHEMBL3517392 | 1.00 | ROCK2 (0.52) | ROCK2ROCK1CCR2SCN1ASCN8A | |
| SCHEMBL3517491 | 0.94 | KDM4E (0.51) | ROCK2ROCK1KDM4EGAA | |
| SCHEMBL3517988 | 0.74 | NOS2 (0.58) | KDM4E | |
| SCHEMBL3516223 | 0.74 | BACE1 (0.49) | KDM4E | |
| SCHEMBL3517465 | 0.74 | NCF1 (0.50) | — | |
| SCHEMBL3514363 | 0.72 | RAB9A (0.47) | KDM4EGAA | |
| SCHEMBL3516890 | 0.72 | CNR2 (0.69) | — | |
| SCHEMBL13326542 | 0.71 | DRD2 (0.65) | ROCK2ROCK1CCR2MALT1OPRK1 | |
| SCHEMBL3517890 | 0.71 | SMN1; SMN2 (0.50) | KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | ROCK2 2531/4885ROCK1 1281/4885CCR2 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.